{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-021868","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.019402+00:00","generated_at":"2026-05-15T08:28:02.292920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicara reports FY2025 net loss $138M; cash $414.8M; raises $161.8M in public offering","bullets":["Net loss Q4 2025 $37.4M, full year $138.0M vs $21.0M and $68.0M in 2024.","R&D expenses $33.0M Q4, $125.1M full year; G&A $8.1M Q4, $30.5M full year.","Cash & securities $414.8M at Dec 31, 2025; added $161.8M net from Q1 2026 offering; expected runway into H1 2029.","Selected 1500mg weekly ficerafusp alfa for Phase 3; initiated FORTIFI-HN01 trial; interim analysis expected mid-2027.","Developing a loading and every-three-week maintenance dose for potential U.S. approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-021868","json":"https://secwatch.observer/filing/0001628280-26-021868.json","markdown":"https://secwatch.observer/filing/0001628280-26-021868.md","text":"https://secwatch.observer/filing/0001628280-26-021868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026021868/0001628280-26-021868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026021868/bcax-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:28:02.292920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90a0683d59be16d2c984f8028bcba4975ab1ee27","claim":"Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.","evidence_excerpt":"On March 30, 2026, Bicara Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026021868/0001628280-26-021868-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}